Deucravacitinib Demonstrates Significantly Greater PASI Reductions in Plaque Psoriasis; Results from the POETYK PSO-1 trial showed significantly greater improvements in patients receiving deucravacitinib compared with placebo or apremilast.

Press/Media

Period22 Oct 2023

Media coverage

2

Media coverage

  • TitleDeucravacitinib Demonstrates Significantly Greater PASI Reductions in Plaque Psoriasis; Results from the POETYK PSO-1 trial showed significantly greater improvements in patients receiving deucravacitinib compared with placebo or apremilast.
    Media name/outletConsultant Live
    Country/TerritoryUnited States
    Date22/10/23
    PersonsMark Lebwohl
  • TitleDeucravacitinib Demonstrates Significantly Greater PASI Reductions in Plaque Psoriasis
    Media name/outletHCP Live
    Country/TerritoryUnited States
    Date22/10/23
    PersonsMark Lebwohl